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Abstract
Background: The human asialoglycoprotein receptor (ASGPR) is composed of two polypeptides, designated H1 and H2.
While variants of H2 have been known for decades, the existence of H1 variants has never been reported.
Principal Findings: We identified two splice variants of ASGPR H1 transcripts, designated H1a and H1b, in human liver
tissues and hepatoma cells. Molecular cloning of ASGPR H1 variants revealed that they differ by a 117 nucleotide segment
corresponding to exon 2 in the ASGPR genomic sequence. Thus, ASGPR variant H1b transcript encodes a protein lacking the
transmembrane domain. Using an H1b-specific antibody, H1b protein and a functional soluble ASGPR (sASGPR) composed
of H1b and H2 in human sera and in hepatoma cell culture supernatant were identified. The expression of ASGPR H1a and
H1b in Hela cells demonstrated the different cellular loctions of H1a and H1b proteins at cellular membranes and in
intracellular compartments, respectively. In vitro binding assays using flourescence-labeled sASGPR or the substract ASOR
revealed that the presence of sASGPR reduced the binding of ASOR to cells. However, ASOR itself was able to enhance the
binding of sASGPR to cells expressing membrane-bound ASGPR. Further, H1b expression is reduced in liver tissues from
patients with viral hepatitis.
Conclusions: We conclude that two naturally occurring ASGPR H1 splice variants are produced in human hepatocytes. A
hetero-oligomeric complex sASGPR consists of the secreted form of H1 and H2 and may bind to free substrates in
circulation and carry them to liver tissue for uptake by ASGPR-expressing hepatocytes.
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Introduction
The asialoglycoprotein receptor (ASGPR), a well-characterized
hepatic lectin, is responsible for the selective binding and
internalization of galactosel/N-acetylgalactosamine-terminating
glycoproteins by hepatic parenchymal cells [1,2]. The activity of
this receptor remains a key factor in the development and
administration of glycoprotein pharmaceuticals, yet its biological
function has remained elusive. Recent studies suggest a function of
ASGPR in hemostatic modulation in response to a reduced
sialylation state of platelets, vWF and possibly other blood
components [3]. Human ASGPR is a hetero-oligomer composed
of a major subunit (H1) and a minor subunit (H2) which are
encoded by two different genes expressed in a molar ratio of ,3:1
[4–6]. Both subunits are type II single-spanning membrane
proteins. Amino acid (aa) sequence indicates that the ASGPR
H1 subunit contains a 40 aa N-terminal cytoplasmic domain, a
,20 aa single-pass transmembrane domain (TMD), an ,80 aa
extracellular stalk (oligomerization) region, and a ,140 aa
functional calcium-dependent acid carbohydrate recognition
domain (CRD) [7].
Three naturally occurring ASGPR H2 splice variants have been
identified, designated H2a, H2b, and H2c [4,8]. Compared to the
smallest splice variant, H2c, the largest isoform H2a contains a 57
nucleotide (nt) insert encoding part of the cytoplasmic domain and
a 15 nt insert encoding a 5 aa sequence near the junction between
the TMD and the ectodomain [4]. The H2a isoform is not
incorporated into native ASGPR complexes on the cell surface.
Rather, the 5 aa sequence encoded by the 15 nt insert, serves as a
cleavage signal that results in proteolysis and the secretion of the
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is present in human serum [10]. ASGPR H2b or H2c isoforms
lacking the 5 aa sequence insert are not proteolytically cleaved and
oligomerize with H1 subunits to form native human ASGPR on
hepatocytes.
While variants of H2 have been known for decades, the
existence of H1 variants has never been reported. During a recent
attempt to clone cDNAs of the human ASGPR H1 subunits, we
made an unanticipated discovery of an H1 splice variant in human
liver tissues and in the human hepatoma cell lines HepG2 and
Huh7. We named the original sequence of ASGPR H1 and its
novel variants H1a and H1b, respectively, in accordance with the
accepted terminology of H2 variants [4,8].
Materials and Methods
Reagents
Unless otherwise noted, all chemicals were purchased from
Sigma-Aldrich (St. Louis, MO). Restriction enzymes, T4 DNA
ligase, and Taq DNA polymerase were purchased from TaKaRa
Biotechnology Co. Ltd. (Dalian, China). TRIzol Reagent,
SuperScript II reverse transcriptase, and all cell culture products
were purchased from Invitrogen (Carlsbad, CA). Monoclonal
mouse anti-hemagglutinin (HA), goat anti-mouse HRP-IgG, and
goat anti-rabbit HRP-IgG antibodies were purchased from
DAKO Corp. (Glostrup, Denmark). Plasmids pXF3H and
pXF1E, mammalian expression vector with the cytomegalovirus
immediate-early promoter and hemagglutinin (HA) tag or
enhanced green fluorescent protein (EGFP) tag individually, were
described previously [11].
Human liver tissues and sera
Human liver tissues from patients were obtained from the
Department of Liver Surgery Center of Tongji Hospital and
stored at 280uC. Human sera for sASGPR purification were
collected from volunteers by the Division of Clinical Immunology,
Tongji Hospital and stored at 280uC. This study had institutional
review board approval. All patients and volunteers who enrolled in
this study provided informed written consent according to the
Helsinki declaration.
Cell culture
HeLa [11], Huh7 [12], HepG2 [13], and HepG2.2.15 cells [13]
with hepatitis B virus (HBV) replication were grown in DMEM/
high glucose supplemented with 10% fetal bovine serum and were
grown at 37uC in H2O-saturated 95% air, 5% CO2. Cells were
seeded into 35 mm plastic dishes for 24 hours before proceeding
with experiments. Huh7.5.1 cells were kindly provided by
Professor Xinwen Chen (Wuhan Institute of Virology, Chinese
Academy of Sciences). For infection with hepatitis C virus, the
cultured JFH-1 strain was used. A complete infection of Huh7.5.1
cells was reached after 6 days post infection [12].
Isolation of total RNA
Total cellular RNA was extracted from human liver and
cultured cells with TRIzol reagent (used according to the
manufacturer’s instructions). Briefly, 100 mg of human liver or
56106 cells were lysed in 1 ml of TRIzol reagent at 22uC for
5 min. Chloroform (200 ml) was added to the lysates, and samples
were mixed by vortexing. Samples were centrifuged at 12,000 g for
15 min at 4uC. The resulting aqueous phase was transferred to an
Eppendorf tube containing 0.5 ml of isopropyl alcohol. After a
10 min incubation, the precipitated RNA was pelleted by
centrifugation at 12,000 g for 10 min at 4uC. The RNA pellet
was resuspended, washed in 1 ml of 75% ethanol, and then
pelleted. The pellet was air-dried and dissolved in 50 ml of water.
Purified RNA was routinely checked on formaldehyde agarose
gels.
Reverse transcription PCR
cDNA templates were synthesized from 1 mg of total RNA,
using SuperScript II reverse transcriptase and an oligo(dT) primer
according to the manufacturer’s instructions. PCR was performed
in a single 50 ml reaction. The PCR program consisted of
incubation for 10 min at 94uC, followed by 35 cycles of 94uC for
60 sec, 55uC for 60 sec, and 72uC for 80 sec, and a final cycle of
10 min at 72uC. PCR products were visualized on a 1.0% agarose
gel stained with ethidium bromide. The primers used for cloning
ASGPR H1 variant cDNAs were: 59-CCG GAA TTC ATG ACC
AAG GAG TAT CAA GAC-39 (P1, sense, nt 180–200), 59-ATT
TGC GGC CGC CTT CCC TTA AAA TCC TAG ATG-39 (P2,
antisense, nt 1145–1165), and the primers used to detect H1
variants were: 59-GAG TAT CAA GAC CTT CAG CAT C-39
(P3, sense, nt 189–210), 59-CTT CAT CTT TCT TCC CAC
ATT-39 (P4, antisense, nt 468–488). H2c cDNA was amplified by
nest PCR. The outer primers used for cloning ASGPR H2c
cDNAs were: 59-CAG CCC TCA GAG CAA CCT-39 (sense, nt
238–255) and 59-CCA TTG AAG AGG CTG ACG A-39
(antisense, nt 1443–1461), the inner primers were: 59-CCG
GAA TTC ATG GCC AAG GAC TTT CAA G-39 (sense, nt
305–323) and 59-ATT TGC GGC CGC CAA AAT CCT CAA
CAG AGA AGC-39 (sense, nt 1289–1309). 20 cycles of first PCR
and 35 cycles of second PCR were performed. The nucleotide
positions are numbered according to the mRNA sequence of
Genbank accession number NM_001671 and NM_080912. The
tagged restriction enzyme cleavage sites are underlined.
Plasmid construction and sequencing
PCR products corresponding to ASGPR H1a, H1b and H2c
cDNAs were excised from the agarose gel, purified using a Gel
Extraction Kit (OMEGA, Victoria BC, Canada), and H1a and
H1b were subcloned into pcDNA3.1(+)/neo via the EcoRI and
NotI restriction sites to yield plasmids pcDNA3.1-H1a and
pcDNA3.1-H1b. H2c cDNA was subcloned into pcDNA3.1 (+)/
zeo (Invitrogen) via the EcoRI and Not I sites. The nucleotide
sequences of the ASGPR H1-inserts were verified by DNA
sequencing (Sangon Biotechnology Co. Ltd., Shanghai, China).
The ASGPR H1a and H1b cDNAs were then subcloned into
pXF3H or pXF1E via the EcoRI and XbaI sites to yield plasmids
pXF3H-H1a, pXF1E-H1a, pXF3H-H1b and pXF1E-H1b re-
spectively, to generate recombinant proteins of H1a and H1b with
HA tag or EGFP tag, for celluar location analysis and WB analysis.
H1a was also subcloned into pIRES/neo (CLONTECH) via the
SalI and EcoRI sites to generate plasmid pIRES-H1a for stable
ASGPR expressing cell line construction.
Real-time fluorescence quantitative PCR (FQ-PCR)
The primer sequences used in real-time FQ-PCR were as
follows: sense primer for ASGPR H1a: 59-TGC TGC TTG TGG
TTG TCT G-39 (P5, nt 331–349), sense primer for ASGPR H1b:
59-GCT CAG AAA AGA CTC CCA G-39 (P6, nt 239–249
combined with nt 367–374), antisense primer for both ASGPR
H1a and H1b: 59-CTT CAT CTT TCT TCC CAC ATT-39 (P4,
nt 468–488). Nucleotide positions were numbered according to the
mRNA sequence of Genbank accession number NM_001671.
Standard curves for ASGPR H1a and H1b cDNA quantification
were made with serial dilutions (103–109 copies) of plasmids
pcDNA3.1-H1a and pcDNA3.1-H1b, respectively. For quantita-
tive real-time PCR analysis of ASGPR H1a and H1b mRNA
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Switzerland) and a Realtime PCR Master Mix Kit (TOYOBO
Co. Ltd., Osaka, Japan) were used according to the manufacturer’s
instructions.
Preparation of anti-ASGPR H1b antibodies
ASGPR H1b-specific epitopes were predicted online
(http://www.imtech.res.in/raghava/bcipep). The peptide SDHH-
QLRKDSQLQE, corresponding to amino acid residues 16–29 of
ASGPR H1b, and peptide-KLH conjugate were synthesized
individually and then used in antibody preparation. Peptide
synthesis and antibody preparation were accomplished by
Proteintech Group, Inc., Wuhan, China. Antibody titer and
specificity were determined by indirect ELISA using a single
peptide antigen. The specificity of one mouse antiserum to
ASGPR H1b was also confirmed by Western blot.
Transfection
The expression plasmids pXF3H-H1a, pXF1E-H1a, pXF3H-
H1b, and pXF1E-H1b were transfected individually or cotrans-
fected into HeLa cells with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
Transfected cells were collected 36 h later and lyzed in sample
buffer for SDS PAGE and Western blot analysis.
Immunofluorescence staining
In brief, pXF3H-H1a and pXF1E-H1b cotransfected cells were
fixed in 50% methanol for 15 min at 4uC and dried at room
temperature, then incubated with mouse anti-HA antibody for 1 h
at 37uC. PBS wash for 3 times, then cells were incubated with PE
labeled goat anti-mouse antibody for 1 h at 37uC. PBS wash for 3
times.
Immunohistochemistry (IHC)
IHC was performed on 4 mm sections cut from paraffin-
embedded human liver tissue specimens. Sections were depar-
affinized in xylene, dehydrated in ethanol, washed in phosphate-
buffered saline (PBS), and treated with 0.3% H2O2 in methanol
for 30 min to block endogenous peroxidase activity. Sections were
blocked with 10% normal goat serum in PBS for 10 min at room
temperature and incubated overnight at 4uC with primary
antibodies. After washing in PBS, the sections were incubated
with Envision solution (a cocktail of peroxidase-labeled polymer
conjugated to goat anti-rabbit and goat anti-mouse immunoglob-
ulins in Tris–HCl buffer; DAKO Corp., Glostrup, Denmark) for
45 min at room temperature. The color reaction was incubated
in 3, 3-diaminobenzidine. Sections were counterstained with
hematoxylin.
Purification of soluble ASGPR (sASGPR)
sASGPR in normal human sera or HepG2 cell supernatants
were purified by lactose-agarose affinity chromatography, modi-
fied from a protocol for purification of ASGPR from liver tissues
[14]. Briefly, a column containing a ,10 ml bed volume of
lactose-agarose (Sigma, St. Louis, MO) was equilibrated with wash
buffer I (50 mM Tris-Cl, pH 7.8, 0.5% Lubrol, 50 mM CaCl2,
1.25 M NaCl) at 4uC. 50 ml normal human pooled sera or 50 ml
HepG2 cell supernatant was mixed with 50 ml lysis buffer
(100 mM Tris-Cl, pH 7.8, 2% Lubrol, 2.5 M NaCl), stirred for
1 h at 4uC, and then centrifuged at 25,000 g for 30 min at 4uC.
Supernatant was removed and incubated with 5 ml 1 M CaCl2
for 30 min on ice. Following a second centrifugation, supernatant
was applied to a 10 ml lactose-agarose column at a flow rate of
25–50 ml per hour at 4uC. The column was washed with 50 ml
wash buffer I and eluted with 42.5 ml elution buffer (20 mM
sodium acetate, pH 5.4, 0.1% Lubrol, 1.25 M NaCl). The eluate
was readjusted with 5 ml of 1 M Tris-Cl, pH 7.8 and 2.5 ml 1 M
CaCl2 and applied to a 1 ml lactose-agarose column at a flow rate
of 25–50 ml per hour at 4uC. After washing with 5 ml wash buffer
II (50 mM Tris-Cl, pH 7.8, 0.1% Lubrol, 50 mM CaCl2, 1.25 M
NaCl), the column was eluted with 10 ml elution buffer. The
eluted proteins were concentrated to 15 mM with Amicon Ultra-4
Centrifugal Filter Devices, 5,000 NMWL (Millipore, Billerica,
MA) and stored at 280uC.
Silver stain
Approx. 500 ng purified protein was separated by 12% SDS-
polyacrylamide gel electrophoresis (PAGE) and stained using a
Silver Stain Plus kit (Bio-Rad Laboratories, Hercules, CA).
Western blot analysis
Purified sASGPR protein or total protein from transfected cells
was separated on 12% SDS-PAGE gels and transferred to
nitrocellulose membranes. Fat-free milk powder solution (10%
w/v) was used for blocking. The membrane was then incubated
with the appropriate primary antibody overnight at 4uC, washed
three times with PBST, and incubated with a 1:5,000 dilution of
horseradish peroxidase-conjugated goat anti-rabbit IgG or goat
anti-mouse IgG. After washing, the proteins were detected by
using Lumi-light Western blotting detection kit (Roche, Rotkreuz,
Switzerland) according to the manufacturer’s instructions.
Construction of stably transfected cell lines expressing
recombinant human ASGPR
HeLa cells were cotransfected with plasmid constructs coding
for two full length subunits of human hepatic ASGPR (H1a and
H2c) that have both been previously shown to be targeted to the
plasma membrane in HepG2 cells [15]. Briefly, plasmids pIRES-
H1a (neo) and pcDNA3.1-H2c (zeo) were transfected to HeLa
cells simultaneously using Lipofectamine 2000. At day 3 after
transfection, cells were passaged and grown under G418 and
zeocin selection. Upon several passages, some stable ASGPR
expressing HeLa cell clones were obtained. The expressing of
ASGPR at the mRNA and protein levels were confirmed by
reverse transcription PCR and immunofluorescence, respectively.
The function of the ASGPR of these clones was also confirmed by
ASOR binding and internalization assay. One stable ASGPR
expressing Hela cell line 4-1-6 was chosen for further study.
In vitro ligand binding
The preparation of ASOR has been described previously [16].
Briefly, 10 mg of human orosomucoid was dissolved in 1 mL of
50 mM acetate buffer, pH 5, and incubated with 0.6 IU of
immobilized neuraminidase for 3 hours at 37uC. Then, neur-
aminidase was removed by centrifugation. The removal of sialic
acid was complete as measured by the thiobarbituric acid assay.
The Alexa Fluor 647 labeled ASOR and sASGPR were prepared
by using Alexa FluorH 647 Protein Labeling Kit according to the
manufacturer’s instruction. HeLa, Huh7, and 4-1-6 cells were
seeded into 24-well plate, and grown to over 90% confluency. The
cells were serum-starved for 20 min before the binding assay, and
then incubated with correspondingly labeled protein for 40 min at
37uC. The medium were removed and the cells were chilled on
ice, then washed twice with ice-cold PBS. The cells were detached
from the plate by trypsin digestion and the MFI of the cells were
analyzed by FACS.
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Two different H1 transcripts are present in human liver
tissues and cultured hepatoma cells
A number of complete ASGPR H1 cDNAs were cloned by RT-
PCR amplification from total RNA of normal adult human liver
tissue. A cDNA sequence of 1,007 bp was expected, based on the
ASGPR H1 mRNA sequence published in Genbank
(NM_001671). However, two ASGPR H1 cDNA species were
obtained and could be separated on an agarose gel (Fig. 1A).
These two ASGPR H1 cDNAs were cloned and sequenced. The
longer sequence, designated ASGPR H1a, was identical to the
known H1 sequence. The shorter sequence, now designated
ASGPR H1b, differs from the H1a by the deletion of 117
nucleotides near the 59 end. The position of the 117 nt deletion in
ASGPR H1b corresponds to nt 250–366 in H1a, starting the nt
numbering according to mRNA sequence NM_001671 (Fig. 1B).
An alignment of the ASGPR H1a and H1b sequences with the
genomic sequence of ASGPR1 (Genbank accession number
NM_000017) revealed that the 117 nt deletion in H1b corre-
sponds to the second exon of the ASGPR1 genomic sequence. The
typical AG/GT 59 consensus splice donor and acceptor sites were
found at each end of Exon 2 (Fig. 1B), strongly suggesting that
ASGPR H1b is generated by alternative splicing of ASGPR
mRNA.
To distinguish the ASGPR H1a and H1b transcripts, primers
were designed to amplify small fragments of 300 and 183 bp for
H1a and H1b transcripts, respectively, allowing clear separation of
the fragments with agarose gel electrophoresis. These two cDNA
fragments were excised from the gel and sequenced to verify that
they were derived from ASGPR H1a and H1b transcripts. Both
ASGPR H1a and H1b transcripts were present in human
hepatoma cell lines HepG2 and Huh7 (Figure S1A). ASGPR
H1b transcripts were also found in liver tissues from patients with
liver diseases. A total of 35 livers were examined, incl. 3 normal
livers, 1 chronic hepatitis, 2 cirrhosis, 1 Hepatic hemangioma
tissue and 28 hepatocellular carcinoma (HCC). In all samples both
H1a and H1b were expressed. The non-hepatic cell line HeLa did
not express ASGPR, as reported, and was used as a control [6].
A real-time RT-PCR assay was used to quantify ASGPR H1a
and H1b transcripts. The real time RT-PCR amplified short
fragments of 158 bp and 133 bp of ASGPR H1a and H1b,
respectively (Figure S1B). The expression levels of ASGPR H1a
and H1b in different liver tissues and cell lines were measured and
presented as copy numbers normalized against beta-actin mRNAs
(Table 1). The data indicated that both splice variants of ASGPR
mRNAs were expressed in normal liver tissues and tumor tissues at
variable levels.
Detection of ASGPR H1b
The amino acid sequences of ASGPR H1a and H1b are
predicted according to the cDNA sequence. ASGPR H1a and
H1b differ in 40 aa that correspond to aa 24–63 in ASGPR H1a.
This region contains the ASGPR H1a transmembrane domain (aa
20–40) and is essential for the localization of ASGPR complexes in
the cell membrane.
Based on the predicted sequence of ASGPR H1a and H1b, a
specific antibody directed to a peptide comprising aa 16–29 (anti-
Table 1. Quantitation of the expression of ASGPR H1 splice variants.
Samples
H1a copy no.
(per 106 b-actin)
H1b copy no.
(per 106 b-actin)
Liver tissues Patient 1 peritumor 55,169 6,992
tumor 14,378 3,401
Patient 2 peritumor 97,396 156,041
tumor 7,867 6,801
Patient 3 peritumor 85,971 86,569
tumor 1,400 2,050
Patient 4 peritumor 47,366 25,208
tumor 13,230 13,792
Normal Hepatic tissue Patient 5 558,644 48,698
Hepatic hemangioma tissue Patient 6 128,514 32,804
Hepatic cell lines HepG2 43,586 937
Huh7 11,359 1,289
doi:10.1371/journal.pone.0012934.t001
Figure 1. Sequence analysis of splice variants of ASGPR H1 and identification of polyclonal antibody that can recognize ASGPR H1b
specifically. (A) Amplification of ASGPR H1a and H1b cDNAs from human liver tissue. Lane 1: DNA ladder. Lane 2: RT-PCR products of total RNA from
human liver tissue. (B) Sequence comparison of ASGPR H1a and H1b transcripts. Upper part: the relevant parts of ASGPR H1 genomic and mRNA
sequences are indicated. The structure of the genomic sequence encoding ASGPR H1 with relevant exons was shown. The 117 bp deletion in ASGPR
H1b mRNA sequence corresponds exactly to the second exon (gray box) of the genomic sequence of ASGPR H1. The primers P1 to P6 used for ASGPR
H1 cDNA cloning and for detection of the variant sequences are marked at corresponding position. Lower part: the sequence alignment of the
genomic sequence of ASGPR H1 and cDNA sequences of H1a and H1b shows the boundaries of the alternatively spliced 117 nt region in the
genomic sequence and the consensus splice donor/acceptor sites (underlined). The difference between the mRNA sequences of ASGPR H1a and H1b
is boxed. Identical nucleotides are indicated by dots; missing nucleotides are indicated by dashes. (C) Specificity analysis of polyclonal antibodies by
western blot. Cell lysates of H1a-HA (lane 1, 3, 5, 7) or H1b-HA (lane 2, 4, 6, 8) transfected cells were separated by SDS-PAGE. Primary antibodies are
used as follows: lanes 1 and 2: anti-HA; lanes 3 and 4: anti-H1; lanes 5 and 6: anti-H1b; lanes 7 and 8: non-immunized mouse serum. The positions of
H1a-HA and H1b-HA are indicated by arrows.
doi:10.1371/journal.pone.0012934.g001
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ASGPR H1b specific peptide, but not unrelated peptides, at
dilutions .1:100,000 in ELISA (Figure S2). Moreover, anti-H1b
was shown to specifically recognize ASGPR H1b, but not H1a, by
Western blot (Fig. 1C).
ASGPR H1a and H1b cDNAs were subcloned into
pcDNA3.1(+)/neo and transfected into HeLa cells. The expression
of both HA-tagged proteins with molecular weights of ,28 kDa
was detected by Western blot with anti-HA antibody and a
commercial antibody to ASGPR H1 (Santa Cruz Biotechnology,
Santa Cruz, CA). Anti-H1b recognized recombinant ASGPR
H1b-HA but not recombinant H1a-HA (Fig. 1C).
Expression and location of ASGPR H1b in human liver
tissues and transfected cells
We further addressed the question whether ASGPR H1b is
synthesized in hepatocytes by IHC. Paraffin sections of human
liver tissue were stained with anti-H1 and anti-H1b primary
antibodies. The anti-H1 antibody, which recognizes both ASGPR
H1a and H1b, stained proteins both at the surface of the cellular
membrane and in the cytoplasm (Fig. 2A). By contrast, the anti-
H1b antibody only stained proteins in the cytoplasm (Fig. 2B).
This indicates that ASGPR H1b is produced in hepatocytes but
does not accumulate at the cellular membrane, consistent with the
fact that the transmembrane domain is missing in ASGPR H1b.
These results were confirmed by the transient expression of H1a
and H1b in Hela cells. The recombination protein H1a-EGFP was
located in the plasma membrane (Fig. 3A), while H1b-EGFP can
only be detected in the cytoplasm (Fig. 3B). Coexpression of both
H1a-HA and H1b-EGFP further displayed that these two H1
variants had different localizations in cells (Fig. 3C).
ASGPR H1b is present in human serum and in the
supernatant from HepG2 cells
The lack of a transmembrane domain in ASGPR H1b suggests
that this protein may be secreted from the cells. Therefore, we
attempted to purify sASGPR from normal human serum and the
supernatant of HepG2 cells by lactose-agarose affinity chroma-
tography. The lactose-agarose affinity column-bound fractions
were subjected to SDS-PAGE and Western blot analysis (Fig. 4).
ASGPR H1b-positive proteins or protein complexes purified from
human sera had molecular weights of approx. 28 kDa, 52 kDa,
60 kDa, 80 kDa, and 95 kDa in silver-stained gels (Fig. 4A). The
fraction purified from HepG2 cell supernatants contained proteins
and complexes with molecular weights of approx. 52 kDa,
60 kDa, and 80 kDa. The components of sASGPR were further
analyzed by Western blot with antibodies specific for H1b (anti-
H1b), H1a and H1b (anti-H1), and ASGPR H2 (anti-H2, Abnova,
Taipei, Taiwan) (Fig. 4B). A protein with the molecular weight of
28 kDa was detected by anti-H1b and anti-H1. All three
Figure 2. Localization of ASGPR H1b protein in human liver tissue by immunohistochemistry. (A) Paraffin sections of human liver tissue
were stained with anti-H1 antibody. Staining of both the surface of the cellular membrane (red arrow) and the cytoplasm are observed. (B) Paraffin
sections of human liver tissue were stained with anti-H1b antibody. Only cytoplasmic staining is observed. (C) Negative control, stained with sera
from non-immunized mice.
doi:10.1371/journal.pone.0012934.g002
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band at 60 kDa was recognized only by anti-H1 (Fig. 4B). It has
been reported previously that the subunits of ASGPR form protein
complexes that are stable even after denaturation in SDS-PAGE
sample buffer containing SDS and b-mercaptoethanol. Therefore,
we interpret the banding pattern on SDS-PAGE as follows: the
protein band at 28 kDa represents the monomeric form of
ASGPR H1b. The bands at 52 kDa and 95 kDa appear to be
heterodimeric complexes of ASGPR H1b and H2. The remaining
band, at 60 kDa, likely represents a homodimer of ASGPR H1a.
However, the bands at 95 kDa and 28 kDa were not detected in
HepG2 cell culture supernatants (Fig. 4B).
Binding of ASOR to ASGPR-expressing cells is reduced in
the presence of sASGPR
To determine whether the presence of the soluble form of
ASGPR affects the function of membrane-bound ASGPR, Huh7
cells and the stably transfected cell line 4-1-6 expressing
membrane-bound ASGPR were incubated with Alexa Fluor
647-labeled ASOR (A-ASOR) alone, or with A-ASOR pre-
incubated with s-ASGPR or BSA. Compared with adding A-
ASOR alone, the binding of ASOR to cells was significantly
reduced in the presence of sASGPR in the medium, while no
change of ASOR binding was observed in the presence of BSA.
HeLa cells were used as a negtive control and did not show any
binding of A-ASOR (Fig. 5A). Over expression of H1b alone in
Huh7 cells or expression of H1b alone in 4-1-6 cells by H1b
expression plamid transfection showed no effect on ASOR binding
to cells (Figure S3). These results suggest that sASGPR as a
complex is able to bind to ASOR, and pose a competition to the
binding between membrane ASGPR and ASOR.
Binding of sASGPR to ASGPR-expressing cells was
increased in the presence of ASOR
We next addressed the question of whether sASGPR itself can
bind to membrane-bound ASGPR expressing cells or not. HeLa
cells, Huh7 cells and cell line 4-1-6 were incubated with Alexa
Fluor 647 labeled sASGPR (A-sASGPR) alone or with A-sASGPR
combine ASOR or BSA. All cells showed a nonspecific binding
with A-sASGPR since this binding could be significantly blocked
by adding BSA to the system (Fig. 5B). Interestingly, the binding of
sASGPR to Huh7 and 4-1-6 cells increased significantly by adding
ASOR to the system (Fig. 5B). However, the binding of sASGPR
to Hela cells did not change in the presence of ASOR. These
results suggest that ASOR is able to enhance the binding of
sASGPR to cells expressing membrane-bound ASGPR. It is likely
that sASGPR and ASOR form complexes, which are able to
interact with membrane-bound ASGPR on the cell surface.
H1b expression is reduced in HepG2.2.15 cells and HCV-
infected Huh7.5.1 cells
Previous reports indicated that ASGPR levels are decreased in
some liver diseases [17]. To determine whether there were any
changes in H1a and H1b expression in different liver diseases, we
Figure 3. Localization of ASGPR H1b protein in transfected cells. (A) Fusion proteins of the two variants of ASGPR H1 subunit were designed
to trace their cellular locations. Both ASGPR H1a and H1b were fused to EGFP in the vector pXF-1E. In pXF-3H-H1a, ASGPR H1a was expressed with an
N-terminal HA tag. (B) Transient expression of EGFP-ASGPR H1a in HeLa cells by transfection with the plasmid pXF1E-H1a. Fluorescence signal of both
the surface of the cellular membrane and the cytoplasm was observed. (C) Transient expression of EGFP-ASGPR H1b in HeLa cells by transfection with
the plasmid pXF1E-H1b. The EGFP-H1b protein is only located in the cytoplasmic compartment. (D) Transient co-expression of EGFP-ASGPR H1a and
H1b in HeLa cells by transfection with plasmids pXF3H-H1a and pXF1E-H1b. After co-transfection with both plasmids, HeLa cells were stained with
anti-HA antibody and corresponding PE-labeled second antibody to detect ASGPR H1a.
doi:10.1371/journal.pone.0012934.g003
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hepatoma cells with real-time PCR (Fig. 6A and 6B). Both H1a
and H1b expression were decreased by approx. 60% in
HepG2.2.15 cells with active HBV replication compared to
HepG2 cells. Similarly, a reduction of H1a and H1b expression
was measured in HCV-infected Huh7.5.1 cells compared to
uninfected Huh7.5.1 cells. HBV gene knockdown by RNAi
partially restored H1a and H1b expression in HepG2.2.15 cells
(data not shown). Further, HepG2 cells have a higher H1a/H1b
ratio than Huh7 cells and liver tissues. Both HBV and HCV
infection had no effect on the H1a/H1b ratio (Fig. 6C).
Discussion
In this study, two distinct ASGPR H1 cDNAs, designated H1a
and H1b, were cloned and sequenced. Sequence data suggest that
these ASGPR H1 cDNAs represent splice variants of the ASGPR
pre-mRNA. Compared with ASGPR H1a, a region of 117
nucleotides corresponding to the second exon of the ASGPR H1
genomic sequence is deleted in H1b, most likely by alternative
splicing. At the protein level, the second exon encodes a
transmembrane domain that is critical for membrane anchoring
of the H1 protein [18,19]. The lack of the transmembrane domain
predicts that variant H1b is unable localize to the cell surface.
Using a specific antibody that discriminates between ASGPR H1a
and H1b, we detected ASGPR H1b protein in normal human sera
and in the supernatant of hepatoma cells, indicating that it is
secreted by these cells. Interestingly, the secreted forms of ASGPR
H1 and H2 were found to co-exist in complexes and are
apparently functional, because ASGPR proteins in sera and cell
supernatants are able to bind to lactose-sepharose. In culture
supernants of hepatoma cells HepG2, two bands representing
sASGPR complexes at 28 kD and 95 kD were not detected. A
possible reason of this observation is the very low expression level
of H1b in HepG2 cells (Tab. 1). Only the major form consisting
H1a, H1b, and H2 was produced, while other minor forms like the
28 kDa band (considered as the monomeric form of H1b) and the
95 kDa band (considered to be complexes of ASGPR H1b and
H2) are apparently not synthesized at a sufficient level.
In previous work, ASGPR minor subunit H2 was shown to be
secreted [9]. Both secreted forms of ASGPR H1 and H2 contain
the stalk domains that are presumably required for hetero-
oligomeric ASGPR complex formation [20]. It has been
confirmed that the high affinity and specificity of binding to
typical ASGP ligands are the result of multiple carbohydrate
recognition domains in a hetero-oligomeric ASGPR complex
binding to multiple complementary Gal/GalNAc residues in a
glycan ligand containing multiple nonreducing termini [21,22].
Though it was possible to synthesize and study homo-oligomeric
ASGPR complexes, only ASGPR homo-oligomers could bind to
typical ASGP ligands [23–27].
Secreted forms have been found for many membrane receptors
[28]. In some cases, cleavage of the wild-type receptor occurs at
the cell surface [29]. In other cases, alternative splicing creates
truncated mRNAs encoding proteins that lack a transmembrane
domain and are secreted [30]. In the case of the ASGPR H2a,
alternative splicing creates a transcript containing an extra mini-
exon, which plays a role in the cleavage and secretion of the
ectodomain [9]. Alternative splicing is an effective mechanism for
generating multiple protein isoforms with diverse functions from a
single gene. In most cases, protein isoforms that arise from
alternative splicing of a single gene transcript share extensive
Figure 4. Analysis of functional sASGPR in serum and supernatant of HepG2 cells by SDS-PAGE and western blot. (A) SDS-PAGE. Lane
1: protein marker. Lane 2: functional sASGPR purified from normal human serum. Lane 3: functional sASGPR purified from supernatant of HepG2 cells.
The positions of the fractions are indicated by arrows. (B) Western blot. Functional sASGPR purified from normal human serum (Lanes 1–3) and
supernatant of HepG2 cells (Lanes 4–6) were separated by SDS-PAGE. Primary antibodies used are as follows: lanes 1 and 4: anti-H1; lanes 2 and 5:
anti-H1b; lanes 3 and 6: anti-H2.
doi:10.1371/journal.pone.0012934.g004
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PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12934Figure 5. Ligands binding assay. The binding of fluorescence labeled A-ASOR (A) and A-sASGPR (B) to cells was determined by FACS. (A) Huh7
cells and cell line 4-1-6 were incubated with A-ASOR alone, or with A-ASOR in the presence of s-ASGPR or BSA. Binding of A-ASOR were determined
by MFI. HeLa cells were used as a negtive control. The MFI value of the sample with A-ASOR alone was set as 100%. (B) HeLa cells, Huh7 cells, and the
ASGPR-expressing cell line 4-1-6 were incubated with A-sASGPR alone, or with A-sASGPR in the presence of ASOR or BSA. Binding of A-sASGPR was
determined by MFI. The MFI value of the sample with A-sASGPR alone was set as 100%.
doi:10.1371/journal.pone.0012934.g005
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12934Figure 6. ASGPR H1b expression in hepatoma cells with and without viral replication. The expression levels of ASGPR H1a (A) and H1b (B)
transcripts were determined by real-time PCR. The mRNA levels of ASGPR H1 variants in HepG2 cells HepG2.2.15 with HBV replication, Huh7.5.1 cells,
and HCV infected Huh7.5.1 cells were determined. The expression levels of ASGPR H1 in HepG2 and Huh7.5.1 cells were set as 100%. (C) The ratio of
H1a/H1b expressed in hepatoma cells.
doi:10.1371/journal.pone.0012934.g006
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thus allowing the fine tuning of specific protein functions [31,32].
Despite extensive studies, the physiological function of ASGPR
has not yet been established [33]. The most rational model for the
function of ASGPR seems to be the galactosyl homeostasis
hypothesis, proposed by Weigel [34]. This model recognizes that
Gal- and GalNAc-containing glycoconjugates are important —
and often critical — molecules in the wide array of cell-cell or cell-
matrix interactions with many different cognate lectins in tissues
throughout the body. Some of these lectin-glycoconjugate
interactions likely occur during development, when ASGPR is
not expressed. In adult tissues, the maintenance of these cell-cell or
cell-matrix interactions requires a continuous participation of Gal/
GalNAc-specific lectins or receptors with Gal/GalNAc glycocon-
jugates. Therefore, the introduction of any soluble Gal/GalNAc
glycoconjugate (due to normal tissue turnover, injury, diet, disease,
etc.) will compete for endogenous cell-cell or cell-matrix
interactions between one or more Gal/GalNAc glycoconjugates
and their lectin receptors. This competition can result in
disruption of tissue organization, cell growth regulation or other
homeostasis functions in tissues. The hepatic ASGPR system is
proposed to be responsible for removing deleterious glycoconju-
gates from the circulation. In this light, sASGPR may be
important to quickly bind soluble Gal/GalNAc glycoconjugates
in the blood, prevent their interaction with normal cells and tissues
until they are cleared in the liver (Fig. 7). This hypothesis of the
function of sASGPR was supported by the results of our in vitro
binding assay. The inhibition of ASOR binding to cells by
sASGPR indicated that they can function in binding asialoglyco-
proteins in the plasma and preventing their interaction with the
cell surface receptor, thus prolonging their life time in the
circulation. The increased sASGPR binding to cells by ASOR
further demonstrated that ASOR-sASGPR complex can still be
captured by membrane ASGPR of hepatocytes and finally be
removed from the circulation.
Hepatic ASGPR is thought to be a potential liver-specific
receptor for many viruses [35–38]. Antibodies to ASGPR were
found in more than 80% of patients with chronic-active
autoimmune-hepatitis (AIH), more than 70% of patients with
hepatitis B, and about 20% of patients with primary biliary
cirrhosis. The titer of ASGPR antibody in patients with AIH
correlates with biopsy-proven periportal inflammatory activity
Figure 7. Possible physiological function of sASGPR. This diagram depicts the dynamic metabolic turnover of Gal/GalNAc glycoconjugates and
their removal by the liver, as described by the Gal/GalNAc homeostasis hypothesis. Various tissues synthesize and secrete different Gal/GalNAc-
specific lectins (black half circles) and Gal/GalNAc-containing glycoconjugates (red or blue full circles). The maintenance of these cell-cell or cell-matrix
interactions requires the continuous participation of these molecules. Normal tissue turnover, injury, diet, disease, or other events may cause Gal/
GalNAc glycoconjugates to be released into the blood. These soluble Gal/GalNAc glycoconjugates will be recognized and bound by sASGPR until
they are transported safely to the liver, where they will be removed and degraded by the hepatic ASGPR system (molecules undergoing intracellular
degradation are indicated by yellow full circles). Without the help of sASGPR, soluble Gal/GalNAc glycoconjugates will compete for the endogenous
cell-cell or cell-matrix interactions between one or more Gal/GalNAc glycoconjugates and their lectin receptors before they can be removed by the
hepatic ASGPR system. This competition could result in the disruption of normal tissue organization, cell growth regulation, or other functions
necessary for normal healthy tissue homeostasis.
doi:10.1371/journal.pone.0012934.g007
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with alcoholic cirrhosis of the liver [42]. Therefore, the function of
sASGPR in human diseases should also be assessed. As shown in
Fig. 6, the expression of ASGPR H1b transcripts in HBV- or
HCV-infected cells was significantly reduced compared to
uninfected cells. This suggests that the expression of sASGPR
may inversely correlate with the pathology of hepatitis virus
infection.
Supporting Information
Figure S1 Sequence analysis and RT-PCR detection of splice
variants of ASGPR H1. (A) Detection of ASGPR H1b transcript
in HepG2 cells and Huh7 cells. Lane 1: DNA ladder. Lane 2: RT-
PCR products of total RNA from HepG2 cells. Lane 3: RT-PCR
products of total RNA from Huh7 cells. Lane 4: RT-PCR
products of total RNA from HeLa cells. (B) Lane 1: DNA ladder.
Lane 2: H1a detected in real time FQ-PCR. Lane 3: H1b detected
in real time FQ-PCR.
Found at: doi:10.1371/journal.pone.0012934.s001 (0.96 MB
TIF)
Figure S2 Preparation and identification of polyclonal antibody
recognizing ASGPR H1b specifically (anti-H1b). (A) Sequence
comparison of ASGPR H1a and H1b. The 117 nt deletion in
ASGPR H1b contains the entire transmembrane domain (TMD)
and part of the cytoplasmic domain of ASGPR H1a. An H1b
peptide SDHHQLRKDSQLQE corresponding to an ASGPR
H1b specific sequence was synthesized for immunization to
generate an anti-H1b antiserum. (B) Determination of the titer
of anti-H1b antibody by indirect ELISA. The antiserum to the
ASGPR H1b specific sequence was diluted serially and tested
against the ASGPR H1b peptide and compared with a control
serum. The anti-H1b serum was reactive against the peptide at a
dilution over 1:100,000. In contrast, the control serum was not
reactive to ASGPR H1b peptide. (C) The specificity of anti-H1b
antiserum. The anti-H1b serum was tested against ASGPR H1b
peptide and an unrelated peptide. The anti-Hb1 shows no
reactivity to the unrelated peptide, indicating the specificity
binding to the H1b peptide of anti-H1b.
Found at: doi:10.1371/journal.pone.0012934.s002 (0.80 MB TIF)
Figure S3 Over expression of H1b alone does not effect ASOR
binding. Plasmid pcDNA3.1-H1b was transfected to Huh7 cells
and cell line 4-1-6. Cells were then incubated with fluorescence
labeled A-ASOR, The binding of A-ASOR to cells was
determined by FACS. Binding of A-ASOR was determined by
MFI. The MFI value of the sample with A-ASOR alone was set as
100%.
Found at: doi:10.1371/journal.pone.0012934.s003 (0.01 MB TIF)
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